Paul Clancy
Chairman bij XILIO THERAPEUTICS, INC.
Vermogen: 2 M $ op 31-03-2024
Actieve functies van Paul Clancy
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| INCYTE CORPORATION | Director/Board Member | 20-01-2015 | - |
| Independent Dir/Board Member | 20-01-2015 | - | |
| XILIO THERAPEUTICS, INC. | Independent Dir/Board Member | 23-07-2020 | - |
| Chairman | 16-06-2022 | - | |
| Director/Board Member | 23-07-2020 | 16-06-2022 | |
| EXACT SCIENCES CORPORATION | Director/Board Member | 18-03-2021 | - |
| Independent Dir/Board Member | 18-03-2021 | - | |
Stromedix, Inc.
 Stromedix, Inc. Pharmaceuticals: MajorHealth Technology Stromedix, Inc. develops novel drugs to treat fibrosis and fibrotic organ failure. The company was founded by Michael Gilman in 2006 and is headquartered in Cambridge, MA. | Director/Board Member | - | - |
| Corporate Secretary | - | - | |
Sionna Therapeutics, Inc.
 Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan. | Chairman | 06-06-2022 | - |
Loopbaan van Paul Clancy
Eerdere bekende functies van Paul Clancy
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. | Director/Board Member | 24-09-2013 | 13-06-2023 |
| Independent Dir/Board Member | 24-09-2013 | 13-06-2023 | |
| ALEXION PHARMACEUTICALS, INC. | Director of Finance/CFO | 01-07-2017 | 01-11-2019 |
| BIOGEN INC. | Director of Finance/CFO | 01-01-2003 | 13-06-2017 |
| Sales & Marketing | 01-01-2001 | 01-01-2003 | |
Biogen Idec, Inc. (North Carolina)
 Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The private company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016. | Director of Finance/CFO | - | 13-06-2017 |
| ░░░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
| ░░░░░░░░░ | - | - | |
| ░░░░░░ ░░░░ ░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Opleiding van Paul Clancy
| Babson College | Undergraduate Degree |
| Columbia Business School | Masters Business Admin |
Statistieken
Internationaal
| Verenigde Staten | 15 |
Operationeel
| Director/Board Member | 6 |
| Director of Finance/CFO | 4 |
| Independent Dir/Board Member | 4 |
Sectoraal
| Health Technology | 10 |
| Consumer Services | 3 |
| Consumer Non-Durables | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 6 |
|---|---|
| INCYTE CORPORATION | Health Technology |
| PEPSICO, INC. | Consumer Non-Durables |
| BIOGEN INC. | Health Technology |
| EXACT SCIENCES CORPORATION | Health Technology |
| AGIOS PHARMACEUTICALS, INC. | Health Technology |
| XILIO THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 6 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Bioverativ Therapeutics, Inc.
 Bioverativ Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bioverativ Therapeutics, Inc. develops pharmaceutical products. It develops medicines for chronic diseases such as hemophilia, anemia, multiple sclerosis, and autoimmune disorders. The company is headquartered in Cambridge, MA. | Health Technology |
Stromedix, Inc.
Stromedix, Inc. Pharmaceuticals: MajorHealth Technology Stromedix, Inc. develops novel drugs to treat fibrosis and fibrotic organ failure. The company was founded by Michael Gilman in 2006 and is headquartered in Cambridge, MA. | Health Technology |
Biogen Idec New Ventures, Inc.
 Biogen Idec New Ventures, Inc. Investment ManagersFinance Founded in 2004, Biogen Idec New Ventures is the corporate venture group of Biogen Idec, Inc. In 2003, Biogen and IDEC Pharmaceuticals merged to create Biogen Idec, Inc. (NASDAQ: BIIB) | Finance |
Biogen Idec, Inc. (North Carolina)
Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The private company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016. | Health Technology |
Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan. | Health Services |
- Beurs
- Insiders
- Paul Clancy
- Ervaring
